Humacyte, Inc. (HUMAW) NASDAQ

0.09

+0.0003(+0.34%)

Updated at March 30 03:59PM

Currency In USD

Humacyte, Inc.

Address

2525 East North Carolina Highway 54

Durham, DE 27713

United States of America (the)

Phone

919 313 9633

Sector

Healthcare

Industry

Biotechnology

Employees

218

First IPO Date

December 01, 2020

Key Executives

NameTitlePayYear Born
Laura E. NiklasonFounder, President, Chief Executive Officer & Director905,4361963
Shamik J. ParikhChief Medical Officer514,7191973
Dale A. SanderChief Financial Officer, Chief Corporate Development Officer & Treasurer704,1891960
Heather ConnellySenior Vice President of Quality0N/A
Yang CaoChief Regulatory Officer01966
William John ScheesseleChief Commercial Officer01972
Lisa MolyneuxExecutive Vice President of Enterprise Planning & Analysis0N/A
Sabrina OsborneChief People Officer0N/A

Description

Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.